Return to study ST001237 main page
MB Sample ID: SA089174
| Local Sample ID: | CA209025-114-56_baseline |
| Subject ID: | SU001305 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR001320 |
| Treatment Summary: | CA209025 (CheckMate 025, NCT01668784) was a phase 3 study of nivolumab in comparison with everolimus for treatment of advanced renal cell carcinoma (RCC). The study was stratified according to region (United States or Canada, Western Europe, and the rest of the world), Memorial Sloan Kettering Cancer Center (MSKCC) prognostic risk group, and the number of previous antiangiogenic therapy regimens (one or two) for advanced renal cell carcinoma. The MSKCC prognostic risk is based on the presence of zero (favorable risk), one (intermediate risk), or two or three (poor risk) of the following prognostic factors: anemia, hypercalcemia, and poor performance status. Nivolumab was administered at a dose of 3 mg per kilogram of body weight as a 60-minute intravenous infusion every 2 weeks and everolimus was administered orally as a daily dose of 10 mg. |
| Treatment Protocol ID: | NCT01668784 |
